Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elvira Favoino

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Annals of the New York Academy of Sciences|August 30, 2005
CD20 mimicry by a mAb rituximab-specific linear peptide: a potential tool for active immunotherapy of autoimmune diseasesFederico Perosa, Elvira Favoino, Maria Antonietta Caragnano, et al.
Blood|October 15, 2005
Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursorFederico Perosa, Elvira Favoino, Maria Antonietta Caragnano, et al.
Autoimmunity Reviews|January 15, 2014
Raynaud's phenomenon: from molecular pathogenesis to therapyMarcella Prete, Maria Celeste Fatone, Elvira Favoino, et al.
Immunology Letters|September 25, 2004
Human CD4 mimicry by anti-idiotypic monoclonal antibody 16D7 is based on a conformational epitopeFederico Perosa, Elvira Favoino, Maria Antonietta Caragnano, et al.
Blood Cells, Molecules & Diseases|November 11, 2008
Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet countFederico Perosa, Carla Minoia, Elvira Favoino, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 21, 2007
Identification of an antigenic and immunogenic motif expressed by two 7-mer rituximab-specific cyclic peptide mimotopes: implication for peptide-based active immunotherapyFederico Perosa, Elvira Favoino, Chiara Vicenti, et al.
Autoimmunity Reviews|May 20, 2008
Rheumatic disorders as paraneoplastic syndromesVito Racanelli, Marcella Prete, Carla Minoia, et al.
Clinical Case Reports|February 23, 2024
Classic pyoderma gangrenosumMarcella Prete, Vito Racanelli, Patrizia Leone, et al.
International Journal of Molecular Sciences|May 14, 2020
SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological TreatmentMarcella Prete, Elvira Favoino, Giacomo Catacchio, et al.
International Journal of Molecular Sciences|April 21, 2019
CD20-Mimotope Peptides: A Model to Define the Molecular Basis of Epitope SpreadingElvira Favoino, Marcella Prete, Giacomo Catacchio, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Annals of the New York Academy of Sciences|August 30, 2005
CD20 mimicry by a mAb rituximab-specific linear peptide: a potential tool for active immunotherapy of autoimmune diseasesFederico Perosa, Elvira Favoino, Maria Antonietta Caragnano, et al.
Blood|October 15, 2005
Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursorFederico Perosa, Elvira Favoino, Maria Antonietta Caragnano, et al.
Autoimmunity Reviews|January 15, 2014
Raynaud's phenomenon: from molecular pathogenesis to therapyMarcella Prete, Maria Celeste Fatone, Elvira Favoino, et al.
Immunology Letters|September 25, 2004
Human CD4 mimicry by anti-idiotypic monoclonal antibody 16D7 is based on a conformational epitopeFederico Perosa, Elvira Favoino, Maria Antonietta Caragnano, et al.
Blood Cells, Molecules & Diseases|November 11, 2008
Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet countFederico Perosa, Carla Minoia, Elvira Favoino, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 21, 2007
Identification of an antigenic and immunogenic motif expressed by two 7-mer rituximab-specific cyclic peptide mimotopes: implication for peptide-based active immunotherapyFederico Perosa, Elvira Favoino, Chiara Vicenti, et al.
Autoimmunity Reviews|May 20, 2008
Rheumatic disorders as paraneoplastic syndromesVito Racanelli, Marcella Prete, Carla Minoia, et al.
Clinical Case Reports|February 23, 2024
Classic pyoderma gangrenosumMarcella Prete, Vito Racanelli, Patrizia Leone, et al.
International Journal of Molecular Sciences|May 14, 2020
SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological TreatmentMarcella Prete, Elvira Favoino, Giacomo Catacchio, et al.
International Journal of Molecular Sciences|April 21, 2019
CD20-Mimotope Peptides: A Model to Define the Molecular Basis of Epitope SpreadingElvira Favoino, Marcella Prete, Giacomo Catacchio, et al.
Pageof 5